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Abstract
Growth hormone (GH) is used to treat short stature and growth failure associated with
growth disorders. Birth size and GH status variably modulate response to GH therapy.
The aim of this study was to determine the effect of birth size on response to GH
therapy, and to determine the impact of GH status in patients born small for gestational
age (SGA) on response to GH therapy. Data from the prospective, non-interventional
American Norditropin Studies: Web-Enabled Research (ANSWER) Program was analyzed
for several growth outcomes in response to GH therapy over 3 years. GH-naïve children
from the ANSWER Program were included in this analysis: SGA with peak GH ≥10 ng/mL
(20 mIU/L), SGA with peak GH <10 ng/mL (20 mIU/L), isolated growth hormone deficiency
(IGHD) born SGA, IGHD not born SGA and idiopathic short stature. For patients with
IGHD, those who did not meet criteria for SGA at birth showed greater improvements
in height SDS and BMI SDS than patients with IGHD who met criteria for SGA at birth.
For patients born SGA, response to GH therapy varied with GH status. Therefore, unlike
previous guidelines, we recommend that GH status be established in patients born SGA
to optimize GH therapy.
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Introduction
Treatment with recombinant human growth hormone
(GH) is widely utilized for improving height in
children with growth failure and conditions in which
it is efficacious, including isolated growth hormone
deficiency (IGHD), idiopathic short stature (ISS) and
small for gestational age (SGA) (1, 2). Although clinical
characteristics of these growth disorders often overlap,
criteria for SGA can be distinguished from those of other
GH disorders in that diagnosis is defined by having a birth
weight and/or length of <−2.0 standard deviation scores
(SDS) for gestational age (3). Retrospective studies indicate
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that approximately one-quarter of children with short
stature (4) and one-third of children with IGHD (5) were
reported to have historical auxological data consistent
with being born SGA.
The effectiveness of GH therapy for increasing shortterm growth rates and adult height in patients with
various growth disorders is well documented (6, 7, 8, 9,
10, 11). For example, 2 years of GH treatment resulted
in an increase from baseline in height SDS (HSDS) in
children with Noonan syndrome, Turner syndrome, ISS,
SGA, IGHD and multiple pituitary hormone deficiency
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(MPHD) (12, 13). Additional studies have also shown
improved growth outcomes in these disorders after 4
to 5 years of GH treatment (7, 9, 14, 15) and improved
growth outcomes associated with starting GH therapy
at an earlier age in prepubertal children and for a longer
duration (9, 12, 13, 15). Despite these demonstrated
benefits of GH replacement therapy (6, 8, 10, 11),
response to treatment with GH is substantially variable
among diagnostic categories and among individuals
with the same disorder (16, 17). For example, greater
linear growth in response to 2 years of GH therapy was
seen in children with SGA compared with those with
IGHD (6). Several factors, including genetics, diagnosis
and biochemical variability, contribute to differences
in responsiveness to GH therapy (18) and complicate
treatment decisions regarding GH therapy, such as when
to start treatment and what dosage is appropriate. In an
attempt to explain variability in response to GH therapy,
several mathematical models have been developed as
practical tools to estimate the response to GH therapy for
the diagnosis of growth hormone deficiency (GHD) (19),
SGA (20) and ISS (21).
The non-interventional American Norditropin
Studies: Web-Enabled Research (ANSWER) Program was
launched in 2002 and designed to assess the real-life
clinical outcomes of pediatric and adult patients treated
with Norditropin as prescribed by physicians according
to standard clinical practice (22). Prospective collection
of data through the US-based ANSWER Program offered
the possibility to gather new insights into GH treatment
effects in specific diagnostic populations, with respect
to patient characteristics, diagnosis, age, sex and
pubertal status. Previous publications from the ANSWER
Program have shown that treatment with GH was
efficacious in increasing HSDS from baseline in children
with IGHD, MPHD, ISS, Noonan syndrome and Turner
syndrome (7, 13). Additionally, some reports have
investigated the effects of baseline characteristics (eg,
HSDS, age, insulin-like growth factor 1 (IGF-I) SDS) on
changes in HSDS in response to GH therapy over time
(12, 13). The analysis described here evaluated growth
outcomes (HSDS, IGF-I SDS and BMI SDS), bone age per
chronological age (BA/CA) and GH dose over 3 years of
treatment in the IGHD, ISS and SGA (GH-sufficient or
-deficient) pediatric populations. The objective of this
report is to assess whether GH responses in patients
born SGA are affected by GH sufficiency/deficiency as
indicated by GH stimulation tests and to evaluate the
effect of birth size on response to GH therapy in patients
with IGHD.
https://ec.bioscientifica.com
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Patients and methods
Study design
Data were extracted from the prospective, noninterventional ANSWER Program, which was launched
in 2002 and aimed to evaluate long-term safety and
effectiveness outcomes of US pediatric and adult patients
treated with Norditropin (somatropin (rDNA origin)
injection; Novo Nordisk A/S) (23). The ANSWER Program
enrolled adults and children prescribed Norditropin for
treatment of GHD or other growth disorders. Informed
consent from patients or their parents or guardians and
approval by the appropriate institutional review board
were obtained prior to study enrollment. Participating
physicians recorded patient histories and physical
examination data using the NovoNet Web-based research
platform. Data collected at initial patient visits included
baseline HSDS, weight, bone age, maximal stimulated
serum GH concentration and serum IGF-I levels. Patient
information collected at follow-up visits included GH
dose/frequency, height, weight, IGF-I concentration and
bone age. GH doses were determined by the treating
physicians (22). Study protocols and documentation
were approved by institutional review boards at each
clinical site, and patients were required to provide
informed consent before the start of any study-related
activities. This study was conducted in accordance
with the Declaration of Helsinki, and all data are
anonymized. The ANSWER Program is guided by Good
Pharmacoepidemiology Practice guidelines for design
and reporting of epidemiologic studies, as defined by
the International Society for Pharmacoepidemiology and
Strengthening the Reporting of Observational studies in
Epidemiology guidelines (22).
Analysis population
The analyses of data from the ANSWER Program described
in this report evaluated changes in growth-related
clinical end points in response to 3 years of treatment
with Norditropin. The analysis population included GH
treatment-naïve children (aged <18 years at the end of
3 years of data collection) diagnosed with ISS, IGHD or SGA
(defined as having a birth weight and/or body length SDS
of <−2.0 for gestational age). ISS was defined as idiopathic
short stature when excluding all other potential causes of
growth failure. Diagnostic classification was determined
by the participating physician who evaluated the patient.
The IGHD population was subdivided based on fulfillment
of SGA criteria according to historical auxological
This work is licensed under a Creative Commons
Attribution 4.0 International License.
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data, and the SGA population was subdivided by peak GH
levels at baseline (<10 vs ≥10 ng/mL, or <20 vs ≥20 mIU/L)
as determined by GH stimulation test. This cutoff point of
10 ng/mL (20 mIU/L) is commonly considered a threshold
indicating normal or below normal GH levels (1);
therefore, for the SGA population, a level of ≥10 ng/mL
(20 mIU/L) was considered indicative of GH sufficiency,
while a peak GH level of <10 ng/mL (20 mIU/L) was
considered to indicate GH deficiency. In the ISS cohort, no
patients had historical auxological data that fulfilled SGA
criteria. Subpopulations are mutually exclusive; patients
with IGHD born SGA were not included in SGA groups.
Only patients who were Tanner stage 1 (prepubertal) at
baseline were included. Patients with prior GH treatment
who started more than 1 week prior to enrollment were
excluded. We also excluded patients with missing birth
weight and/or length information at baseline (enrollment
visit). Participants with missing, inconsistent or improbable
baseline values of key variables (height, BMI, BA, CA, gender
and IGF-I) or any of the GH response end points above were
also excluded. Since many patients were missing baseline
GH peak values and/or IGF-I values and/or BA imaging
values at baseline, we used in lieu of missing any of these
three baseline values the values from the closest visit date
to enrollment date within the interval from 18 months
before to 12 months after the enrollment date.
Variables and statistical analysis
Clinical end points included HSDS, BMI SDS, bone age
per chronological age (BA/CA), insulin-like growth
factor 1 (IGF-I) SDS and GH dose. HSDS and BMI SDS
(z-scores) were calculated from actual height and weight
using standard references provided by the US Centers for
Disease Control and Prevention (24). IGF-I values were
measured locally and transformed into IGF-I SDS based
on age- and sex-related normative values of Brabant
et al. (25). Reported means, including those referring to
change over baseline values, were calculated as a mean
of the patients within each subpopulation. Patients with
missing birth weight and/or length information or with
missing baseline values of key variables (height, BMI, BA,
CA, gender and IGF-I) or any of the clinical end points
were excluded. Only observed values were used in the
analysis; missing values were not imputed. Participants
with missing data for some, but not all, the follow-up
visits were included for the years with available data.
All statistical tests were two-sided and P values ≤0.050
were considered statistically significant. Descriptive
summaries were provided for baseline characteristics
https://ec.bioscientifica.com
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and clinical end points at each year of GH treatment
and reported as mean (standard deviation (s.d.)) unless
otherwise noted. Differences in ΔHSDS and ΔIGF-I SDS
at each year of GH treatment were compared by analysis
of covariance (ANCOVA), with diagnostic population,
gender and baseline age as fixed effect covariates. Leastsquares (LS) means for ΔHSDS and ΔIGF-I SDS at year 3
were estimated using the Tukey–Kramer test. All analyses
were performed using SAS version 9.3 (SAS Institute).

Results
Demographics and baseline characteristics by SGA,
IGHD subpopulations
Of the 14,680 GH-naïve children who enrolled in ANSWER
by the end of July 2016, 882 met all inclusion criteria and
were included in this analysis. The subpopulations in this
analysis were SGA and GH sufficient (peak GH ≥10 ng/mL, or
≥20 mIU/L), SGA with GH deficiency (peak GH <10 ng/mL,
or <20 mIU/L), IGHD born SGA, IGHD not born SGA and
ISS. The majority of these patients were diagnosed with
IGHD and not born SGA (n = 709); the second largest
subpopulation was those diagnosed with IGHD who were
also born SGA (n = 86) (Table 1). Mean BA/CA was not
statistically different among subpopulations, although
statistical differences in means for all other parameters
were found. Mean (s.d.) peak GH (ng/mL) levels were
higher for children born SGA who were GH sufficient
(17.04 (5.08)) compared to those born SGA who were GH
deficient. For children with IGHD, those who met criteria
for SGA had lower mean (s.d.) peak GH (ng/mL) levels
compared to those with IGHD who did not meet criteria
for SGA (6.82 (5.30) vs 7.44 (7.11)). Mean (s.d.) birth
length SDS (BL SDS) was lower for children born SGA who
were GH sufficient (−2.75 (1.97)) compared to those born
SGA who were GH deficient (−2.08 (1.35)). Mean (s.d.)
birth weight SDS (BW SDS) was lower for children born
SGA who were GH sufficient (−2.50 (0.72)) compared to
children born SGA with GH deficiency (−1.89 (1.12)).
GH response and treatment summaries by year after
enrollment and subpopulation
In general, the growth-related outcomes, IGF-I SDS, BMI
SDS and HSDS improved over the 3 years of follow-up,
as shown by mean SDS for these outcomes at each
year after enrollment (Table 2). For all five patient
groups, BA/CA increased slightly from year 1 to year 3.
This work is licensed under a Creative Commons
Attribution 4.0 International License.
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Table 1 Demographics and baseline characteristics by reported diagnosesa.
SGA, peak GH
≥10 ng/mL

n
Male, n (%)
Age, mean (s.d.) (years)
Mean (s.d.)
IGF-I SDS
BA/CA
BMI SDS
Peak GH (ng/mL)
Height SDS
BL SDS
BW SDS
GH dose (mg/kg/day)

SGA (non-IGHD), peak GH
<10 ng/mL

IGHD
born SGA

IGHD not
born SGA

ISS

P value

28
18 (64.3)
7.18 (3.40)

15
6 (40.0)
7.71 (2.75)

86
58 (67.4)
8.32 (3.30)

709
578 (81.5)
9.80 (2.96)

44
37 (84.1)
10.41 (2.35)

<0.001
<0.001

−1.51 (1.34)
0.78 (0.18)
−1.07 (1.51)
17.04 (5.08)
−2.78 (0.71)
−2.75 (1.97)
−2.50 (0.72)
0.05 (0.02)

−1.06 (1.66)
0.79 (0.18)
−0.72 (2.06)
5.72 (2.84)
−2.29 (0.60)
−2.08 (1.35)
−1.89 (1.12)
0.05 (0.02)

−1.22 (1.51)
0.83 (0.19)
−0.41 (1.26)
6.82 (5.30)
−2.56 (0.76)
−3.67 (3.25)
−2.48 (0.91)
0.05 (0.01)

−1.88 (1.55)
0.83 (0.16)
−0.24 (1.28)
7.44 (7.11)
−2.25 (0.78)
0.07 (1.01)
−0.37 (1.08)
0.05 (0.01)

−0.65 (2.08)
0.85 (0.12)
−0.31 (1.06)
14.61 (3.95)
−2.13 (0.46)
−0.35 (0.80)
−0.68 (0.69)
0.06 (0.02)

<0.001
0.43
0.008
<0.001
<0.001
<0.001
<0.001
<0.001

a

Subpopulations are mutually exclusive; patients with IGHD born SGA were not included in SGA groups.
BA/CA, bone age/chronological age; BL, birth length; BMI, body mass index; BW, birth weight; GH, growth hormone; IGF-I, insulin-like growth factor 1; IGHD,
isolated growth hormone deficiency; ISS, idiopathic short stature; s.d., standard deviation; SDS, standard deviation score; SGA, small for gestational age.

Among patients born SGA, mean (s.d.) BMI SDS from year 1
to year 3 increased more for those with GH deficiency
(−0.85 (2.28) to −0.21 (1.11)) compared with those who
were GH sufficient (year 1, −0.90 (1.43); year 3, −0.57
(1.06)). However, differences in mean (s.d.) height SDS
from year 1 to year 3 were greater for patients born SGA
who were GH sufficient (year 1, −2.43 (0.71); year 3,
−1.63 (0.73)) compared to patients born SGA who were
GH deficient (year 1, −1.89 (0.60); year 3, −1.18 (0.79)).
Increase in mean (s.d.) IGF-I SDS was also greater for
patients born SGA with GH deficiency (year 1, −0.11 (1.46);
year 3, 1.19 (2.29)) compared to patients born SGA who
were GH sufficient (year 1, 0.68 (2.17); year 3, 1.40 (1.14)).
Improvements in growth-related outcomes were greater
for IGHD patients who were not born SGA compared to
those with IGHD who were born SGA. Increases in mean
(s.d.) HSDS from year 1 to year 3 were slightly greater for
patients with IGHD not born SGA (−1.86 (0.78) to −1.04
(0.80)) than for patients with IGHD born SGA (−2.08 (0.69)
to −1.34 (0.72)). Similarly, increase in mean (s.d.) BMI SDS
was greater for IGHD patients not born SGA (year 1, −0.18
(1.10); year 3, 0.02 (1.07)) compared to IGHD patients
born SGA (year 1, −0.43 (1.16); year 3, −0.28 (1.03)). Of
note, mean (s.d.) IGF-I SDS increased from 0.19 (1.69) to
1.00 (1.54) from year 1 to year 3 for IGHD patients not
born SGA compared to an increase of 0.96 (1.54) to 1.03
(1.42) for IGHD patients born SGA.

Change from baseline in GH response and treatment
by year after enrollment and subpopulation
Consistent with these response data, mean ΔHSDS relative
to baseline levels progressively increased over each year
https://ec.bioscientifica.com
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of follow-up for each patient subpopulation (Fig. 1).
Increases in mean ΔHSDS were similar between SGA
patients with GH deficiency (0.23 in year 1 to 1.08 in
year 3) and patients born SGA and GH sufficient (0.31 in
year 1 to 1.15 in year 3). Patients with IGHD not
born SGA had a greater increase in mean ΔHSDS (0.35 in
year 1 to 1.19 in year 3) than patients with IGHD born
SGA (0.44 in year 1 to 1.22 in year 3). Patients with ISS
had the lowest mean ΔHSDS of all subgroups at year 3.
Differences by subpopulation in changes in HSDS
from baseline: repeated measurements mixed
model results
To control for potential covariates influencing ΔHSDS
results, differences were also compared by ANCOVA and
adjusted for year of follow-up, gender, baseline age and
baseline HSDS, with an estimated difference from baseline
of 0.5855 (Table 3). Significant differences in ∆HSDS
between subpopulations remained after adjusting for
each of these variables. Additional estimates quantified
differences in ∆HSDS compared with a specific reference
population (ie, the IGHD not born SGA group, which had
the greatest ∆HSDS during GH treatment). Compared to
the IGHD not born SGA population, individuals with ISS
and those born SGA with peak GH ≥10 ng/mL or ≥20 mIU/L
also showed significant improvements in ∆HSDS with
GH treatment. Overall, the study population showed a
significant improvement in ∆HSDS, measured as yearly
change over baseline, by 0.8070 s.d. in year 3 over year 1.
A significant decline in ∆HSDS by approximately 0.059 was
estimated per each year of delay in start of treatment. For
each unit of increase in baseline HSDS, improvement from
GH treatment declined by an estimated 0.1275 ΔHSDS.
This work is licensed under a Creative Commons
Attribution 4.0 International License.
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Values shown are mean SDS for each year after enrollment; bhigher mean SDS indicates better outcomes.
BA/CA, bone age/chronological age; BMI, body mass index; GH, growth hormone; IGF-I, insulin-like growth factor 1; IGHD, isolated growth hormone deficiency; ISS, idiopathic short stature; s.d.,
standard deviation; SDS, standard deviation score; SGA, small for gestational age.

mg/kg/day (s.d.)

Year 3
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a

86
57
0.96 (1.49)
57
0.88 (0.14)
79
−0.34 (1.14)
79
−1.63 (0.72)
72
0.05 (0.01)
28
28
15
15
15
86
14
15
3
7
8
49
1.13 (1.69)
1.40 (1.14) −0.11 (1.46)
0.38 (1.79)
1.19 (2.29)
0.96 (1.54)
7
17
7
8
9
47
0.87 (0.11)
0.91 (0.14)
0.83 (0.11)
0.88 (0.11)
0.88 (0.13)
0.88 (0.17)
26
28
12
13
13
80
−0.90 (1.18) −0.57 (1.06) −0.85 (2.28) −0.34 (1.22) −0.21 (1.11) −0.43 (1.16)
26
28
12
13
13
80
−1.97 (0.77) −1.63 (0.73) −1.89 (0.60) −1.45 (0.71) −1.18 (0.79) −2.08 (0.69)
26
28
12
13
13
75
0.05 (0.01)
0.05 (0.02)
0.05 (0.02)
0.05 (0.02)
0.05 (0.02)
0.04 (0.01)
n
28
IGF-I SDSb, n
20
Mean (s.d.)
0.68 (2.17)
BA/CA, n
11
Mean (s.d.)
0.78 (0.16)
b
BMI SDS , n
27
Mean (s.d.) −0.90 (1.43)
Height SDSb, n
27
Mean (s.d.) −2.43 (0.71)
GH dose, n
26
Mean,
0.05 (0.01)

ISS

Year 2
Year 1
Year 3
Year 2

IGHD not born SGA

Year 1
Year 3
Year 2

IGHD born SGA

Year 1
Year 3
Year 2
Year 1
Year 1

Year 2

Year 3

SGA (non-IGHD), peak GH
<10 ng/mL
SGA, peak GH
≥10 ng/mL

Table 2 GH response outcomes over time by year after enrollment and subpopulationa.

86
709
709
709
44
44
44
51
387
415
400
23
26
20
1.03 (1.42)
0.19 (1.69)
0.80 (1.51)
1.00 (1.54)
0.21 (1.93)
0.58 (0.99)
0.40 (1.29)
61
335
471
437
22
24
20
0.92 (0.12)
0.87 (0.13)
0.89 (0.12)
0.91 (0.10)
0.86 (0.13)
0.88 (0.11)
0.91 (0.10)
79
635
660
664
41
41
42
−0.28 (1.03) −0.18 (1.10) −0.10 (1.13)
0.02 (1.07) −0.25 (0.95) −0.19 (0.93) −0.13 (0.95)
79
635
659
663
41
41
42
−1.34 (0.72) −1.86 (0.78) −1.40 (0.78) −1.04 (0.80) −1.82 (0.48) −1.62 (0.60) −1.34 (0.59)
74
599
629
631
31
32
33
0.05 (0.01)
0.05 (0.01)
0.05 (0.01)
0.05 (0.02)
0.05 (0.01)
0.05 (0.01)
0.05 (0.01)
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Differences by subpopulation in changes in IGF-I
SDS from baseline: repeated measurements mixed
model results
ANCOVA was similarly used to estimate differences in
ΔIGF-I SDS while adjusting for year of follow-up, gender,
baseline age and baseline HSDS. After controlling for each
of these variables, significant differences were observed
between subpopulations in ∆IGF-I SDS (Table 4). The
GH-sufficient SGA subpopulation showed the greatest
improvement from baseline in ΔIGF-I SDS (estimated
0.269 compared with the reference subpopulation (IGHD
not born SGA)). In comparison, the GH-deficient SGA
population had an estimated ΔIGF-I SDS improvement
of −0.305. In the overall study population, ΔIGF-I SDS
compared with year 1 improved significantly in year 2
(estimated 0.5443) and in year 3 (estimated 0.7387).

Mixed models LS means for ∆HSDS and ∆IGF-I SDS
at year 3 by subpopulation
Estimates of ∆HSDS and ΔIGF-I SDS at year 3 were
generated as LS means by assigning mean values for all
other covariates (male, 79%; baseline age, 9.6 years;
enrollment HSDS, −2.27; enrollment IGF-I SDS, −1.57)
(Table 5). The estimate for ∆HSDS at year 3 was higher for
patients born SGA with GH deficiency, with an LS mean
of 1.0575, compared to patients born SGA who were GH
sufficient (LS mean, 0.9713). Conversely, the estimate for
∆IGF-I SDS at year 3 was higher for patients born SGA
who were GH sufficient (LS mean, 2.8806) compared
to patients born SGA who were GH deficient (LS mean,
2.3263). For IGHD patients, those born SGA had a lower
estimated ∆HSDS at year 3 (LS mean, 1.1693) compared to
IGHD patients who were not born SGA (LS mean, 1.2142).
Estimated ∆IGF-I SDS was higher for patients with IGHD
born SGA (LS mean, 2.7341) compared to IGHD patients
not born SGA (LS mean, 2.6273).

Discussion
This analysis of data from the ANSWER Program
demonstrates that treatment with GH resulted in
improved growth outcomes for children with IGHD
or SGA (GH sufficient or deficient) and ISS. With few
exceptions, improvements were shown in all outcomes
(IGF-I SDS, BMI SDS and HSDS) for all population groups
over 3 years of treatment. Increases in ∆HSDS over time
are consistent with results reported in other ANSWER
This work is licensed under a Creative Commons
Attribution 4.0 International License.
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Figure 1
Mean and SDS change from baseline HSDS over
time.

publications (9, 13, 26). Previous publications have
evaluated the effects of gender (26), age (9, 26), diagnosis
(6) and baseline auxological characteristics (BMI, HSDS,
IGF-I) (13) on responses to GH therapy; however, effects
of birth size independent of GH status have not previously
been assessed. In patients born SGA, effect of GH status
(deficiency or sufficiency) on response to GH therapy is
also unknown.
Improvements in mean HSDS were observed for
all patient subpopulations, indicating the benefits of

GH treatment. In the analysis presented here, two
subpopulations of patients with GHD who were born SGA
were compared: those who were primarily diagnosed with
SGA and found to be GH insufficient and those who were
diagnosed with IGHD and whose historical auxological
data fulfilled criteria for SGA. The SGA group who were
GH insufficient showed a greater improvement in HSDS
than patients with IGHD born SGA. Previous reports of
data from the ANSWER Program indicated that increases
in HSDS were similar between patients born SGA and

Table 3 Differences in ΔHSDS from baseline – repeated measurements mixed model results.
Fixed effect

Intercept
Subpopulation indicatorsa
IGHD not born SGA (ref)
SGA, peak GH ≥10 ng/mL
SGA (non-IGHD), peak GH <10 ng/mL
IGHD born SGA
ISS
Year indicators
Year 1 (ref)
Year 2
Year 3
Gender
Female (ref)
Male
Age at baseline
HSDS at baseline

Estimate

95% CI LB

95% CI UB

0.5855

0.4489

0.7221

–
−0.2419
−0.1568
−0.04442
−0.2463
–
0.4553
0.8070
–
0.1062
−0.05898
−0.1275

–
−0.3842
−0.3513
−0.1301
−0.3596
–
0.4312
0.7829
–
0.0427
−0.0677
−0.1612

T-test P value

–
0.4793
0.8311

<0.0001b
–
0.0009
0.1139
0.3089
<0.0001
<0.0001b
–
<0.0001
<0.0001

–
0.1697
−0.05026
−0.09376

–
0.0011
<0.0001
<0.0001

–
−0.09961
0.03766
0.04121
−0.1331

n = 2438 visits by 866 patients.
a
Adjusted for year of follow-up, gender, baseline age, and HSDS; boverall F-test P value.
GH, growth hormone; HSDS, height standard deviation score; IGHD, isolated growth hormone deficiency; ISS, idiopathic short stature; LB, lower bound;
ref, reference; SGA, small for gestational age; UB, upper bound.
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Table 4 Differences in ΔIGF-I SDS from baseline – repeated measurements mixed model results.
Fixed effect

Intercept
Subpopulation indicatorsa
IGHD not born SGA (ref)
SGA, peak GH ≥10 ng/mL
SGA (non-IGHD), peak GH <10 ng/mL
IGHD born SGA
ISS
Year indicators
Year 1 (ref)
Year 2
Year 3
Gender
Female (ref)
Male
Age at baseline
IGF-I SDS at baseline

Estimate

95% CI LB

95% CI UB

0.7326

0.3607

1.1044

T-test P value

–
0.269
−0.305
0.103
−0.6673

–
−0.2715
−1.1046
−0.2124
−1.0982

–
0.8095
0.4946
0.4185
−0.2365

–
0.5443
0.7387

–
0.4027
0.5951

–
0.6858
0.8823

0.0208b
–
0.3289
0.4542
0.5215
0.0024
<0.0001b
–
<0.0001
<0.0001

–
0.3211
−0.01875
−0.6524

–
0.08136
−0.05362
−0.7139

–
0.5609
0.01613
−0.591

–
0.0087
0.2916
<0.0001

n = 1495 visits by 712 patients.
a
Adjusted for year of follow-up, gender, baseline age, and HSDS; boverall F-test P value.
GH, growth hormone; IGF-I, insulin-like growth factor 1; IGHD, isolated growth hormone deficiency; ISS, idiopathic short stature; LB, lower bound; ref,
reference; SDS, standard deviation score; SGA, small for gestational age; UB, upper bound.

those with IGHD (6, 7). The analyses in those studies,
however, did not consider GH sufficiency among patients
born SGA. The data in this report demonstrate the
variability in responses to GH treatment among patients
born SGA depending on GH status. For example, increases
in mean ∆HSDS were greater for patients born SGA who
were GH sufficient than for patients born SGA who were
GH insufficient. However, increases in ∆BMI SDS from a
negative BMI SDS, which is considered a positive response
to GH therapy and indicates that the patient’s BMI is
approaching the normal range, were greater for patients
born SGA who were GH insufficient than for those who
were GH sufficient. In the IGHD group, GH responses
also appeared to be affected by SGA status, as patients
with IGHD not born SGA showed a greater increase in
mean ∆HSDS than patients with IGHD born SGA. Given
the variability in response to GH therapy among SGA
patients, GH status should be considered when setting

treatment goals. Regarding the ISS cohort, while mean
daily GH dose was higher for this patient group (0.06 mg/
kg/day vs 0.05 mg/kg/day for all other groups), these
patients appeared to benefit the least from GH therapy
(eg, change in HSDS and IGF-I from year 1 to year 3 was
the least for the ISS cohort). It is important to note that of
the cohorts analyzed in this study, patients with ISS may
be the most heterogeneous, as their causes of short stature
may be variable. Etiologies may include GH resistance/
diminished responsiveness so that larger dosages
are necessary for clinical responsiveness. Given this
likelihood, it is recognized that growth responses based
upon similar dosages cannot be compared meaningfully.
In addition to HSDS, mean IGF-I SDS also increased
in most patient groups while GH dose remained constant
over the 3-year period in all groups. Although the IGHD
born SGA subpopulation demonstrated similar changes in
HSDS to the other groups, mean IGF-I SDS only increased

Table 5 Mixed models least-squares means for ∆HSDS and ∆IGF-I SDS at year 3.
∆HSDS

∆IGF-I SDS

Pairwise comparison

LS meana

95% CI LB

95% CI UB

LS meana

95% CI LB

95% CI UB

SGA, peak GH ≥10 ng/mL
SGA (non-IGHD), peak GH <10 ng/mL
IGHD born SGA
IGHD not born SGA
ISS

0.9713
1.0575
1.1693
1.2142
0.9676

0.8316
0.8649
1.0878
1.1841
0.857

1.1109
1.2501
1.2508
1.2444
1.0781

2.8806
2.3263
2.7341
2.6273
1.9685

2.3452
1.5323
2.43
2.5004
1.5451

3.4161
3.1202
3.0382
2.7543
2.392

Mixed model results in Tables 3 and 4.
a
Assigned mean values for all other covariates: male = 79%, enrollment age = 9.6 years, enrollment HSDS = −2.27, enrollment IGF-I SDS = −1.57.
GH, growth hormone; HSDS, height standard deviation score; IGF-1, insulin-like growth factor 1; IGHD, isolated growth hormone deficiency; ISS,
idiopathic short stature; LB, lower bound; LS, least squares; SGA, small for gestational age; UB, upper bound.
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from 0.96 to 1.03. In comparison, the other groups with
GH insufficiency demonstrated greater increases in IGF-I
SDS; the IGHD not born SGA group increased from 0.19
in year 1 to 1.00 in year 3, and SGA with GH deficiency
group increased from −0.11 to 1.19; the SGA and GH
sufficient group also showed a greater increase in IGF-I
SDS, from 0.68 in year 1 to 1.40 in year 3.
The repeated measurements model for ∆HSDS derived
from this analysis indicates that older baseline age and
having a lower difference in HSDS at baseline may
reduce the effect of GH treatment on HSDS. The model
is consistent with findings from other analyses on data
from the ANSWER Program that included patients with
GHD, SGA and ISS, which demonstrated that younger
age at baseline and lower baseline HSDS were factors that
were associated with higher ∆HSDS after approximately
4 years of GH treatment (7, 13). This result reiterates
the importance of initiating GH therapy at a young age,
which has been emphasized before.
There are several potential limitations of this study.
Given that the ANSWER Program is an observational
study, there may be variations in data collection due to
the large number of investigators who participated. In
addition, it was at the discretion of the reporting physician
to provide their patient’s diagnosis, and thus, variability
among physicians’ diagnoses contribute to a certain lack
of uniformity. There is also potential for information bias
due to missing or erroneous data points resulting from
misdiagnosis or failure to report confounding variables.
Differences in laboratory assays (eg, IGF-I assays, GH
assays) and diagnostic procedures among sites reporting
information may affect outcomes, and considering
the variability in IGF-I assays, this especially limits
interpretation of IGF-I data. Another potential limitation
is the differences in availability of diagnostic technologies
among clinics; for this reason, some patients may be
missing results for some tests, such as the GH stimulation
test. Further, as noted earlier, there are situations of GH
resistance that may occur within the categorical diagnoses
of both ISS and SGA that are difficult to diagnose or that
are yet to be described.
In conclusion, results of this analysis demonstrate
that the greatest benefits of GH treatment were shown for
patients diagnosed with IGHD who were not born SGA,
those diagnosed with IGHD who were born SGA and
those born SGA who were GH deficient. Of note, among
patients with IGHD, birth size appears to affect response
to GH therapy, as IGHD patients who were not born SGA
showed greater improvements in growth-related outcomes
compared to IGHD patients who were born SGA. Regarding
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patients born SGA, GH responses were variable between
those who were GH sufficient and those who were GH
deficient. While the assessment of GH status in patients
born SGA has not been recommended in the literature or
by existing guidelines, the results reported here suggest
that determining GH status may help explain some of the
variation in response to GH therapy in children born SGA.
Therefore, GH status may be yet another consideration
for GH therapy optimization in these patients. Further
studies, including genetic analyses, are needed to elucidate
additional aspects of SGA that impact growth.
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